Paper36945221
Molecular docking analysis of VEGF with compounds from tomato.
Krishnan M and 4 others. Bioinformation, 2022. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Molecular docking analysis of VEGF with compounds from tomato. Papers, record 36945221. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36945221
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18596824 | VEGF-targeted therapy: mechanisms of anti-tumour activity. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18596824 | PubMed |
| 2 | 10742145 | Mechanisms of angiogenesis and arteriogenesis. | Nat Med | 2000 | https://conductscience.org/library/papers/10742145 | PubMed |
| 3 | 28831824 | VEGF as a potential target in lung cancer. | Expert Opin Ther Targets | 2017 | https://conductscience.org/library/papers/28831824 | PubMed |
| 4 | 26001391 | Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. | Oncologist | 2015 | https://conductscience.org/library/papers/26001391 | PubMed |
| 5 | 15364128 | Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. | Lung Cancer | 2004 | https://conductscience.org/library/papers/15364128 | PubMed |
| 6 | 26980827 | World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. | Adv Nutr | 2016 | https://conductscience.org/library/papers/26980827 | PubMed |
| 7 | 18506025 | Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18506025 | PubMed |
| 8 | 25344762 | Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. | Cancer Chemother Pharmacol | 2014 | https://conductscience.org/library/papers/25344762 | PubMed |
| 9 | 24263190 | VEGF targets the tumour cell. | Nat Rev Cancer | 2013 | https://conductscience.org/library/papers/24263190 | PubMed |
| 10 | 23901264 | Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. | Drug Des Devel Ther | 2013 | https://conductscience.org/library/papers/23901264 | PubMed |
| 11 | 24880938 | Immunotherapy in the treatment of non-small cell lung cancer. | Lung Cancer | 2014 | https://conductscience.org/library/papers/24880938 | PubMed |
| 12 | 21303969 | Lung cancer: New biological insights and recent therapeutic advances. | CA Cancer J Clin | 2011 | https://conductscience.org/library/papers/21303969 | PubMed |
| 13 | 23440996 | Targeting Multidrug Resistant Mycobacterium tuberculosis HtrA2 with Identical Chemical Entities of Fluoroquinolones. | Indian J Pharm Sci | 2012 | https://conductscience.org/library/papers/23440996 | PubMed |
| 14 | 25618350 | Small-molecule library screening by docking with PyRx. | Methods Mol Biol | 2015 | https://conductscience.org/library/papers/25618350 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38137249 | Metabolomics Study of the Effect of Transcription Factor NOR-like1 on Flavonoids in Tomato at Different Stages of Maturity Using UPLC-MS/MS. | Foods | 2023 | https://conductscience.org/library/papers/38137249 | PubMed |
| 37808386 | Anti-quorum sensing activity of Boerhavia diffusa against Pseudomonas aeruginosa PAO1. | Bioinformation | 2023 | https://conductscience.org/library/papers/37808386 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36945221
GET https://conductscience.org/api/papers/v1/36945221/authors